Cover Image
Market Research Report

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

Published by GBI Research Product code 244534
Published Content info 112 Pages
Immediate Delivery Available
Price
Back to Top
Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar
Published: June 12, 2012 Content info: 112 Pages
Description

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar", which provides insights into bone metabolic disease therapeutics until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases. The report also provides the share of generics in global bone metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each of the four indications. The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. The report also includes insights into the bone metabolic diseases R&D product pipeline and explores the competitive landscape, including major players in the bone metabolism therapeutics market. Finally, the report also includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market.

GBI Research's analysis shows that the overall global bone metabolism therapeutics market for the four indications (which includes osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases) was valued at $15 billion in 2010, growing from $10.1 billion in 2002 and indicating a CAGR of 5.2%. GBI Research forecasts the market to grow at a CAGR of 7.7% between 2010 and 2018 to record a sales value of $27.1 billion by 2018. The growth in the bone metabolism therapeutics market is mainly due to the contribution of osteoporosis market. The revenue of osteoporosis market alone has approximately 68% of the total bone metabolism revenue. So, the global bone metabolism market is growing inspite of the declining market nature of the rest of therapeutics areas discussed here.

Scope

  • Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2018 for the three indications - osteoporosis, Paget's disease of bone, hyperparathyroidism and bone metastases.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in the global bone metabolism therapeutics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global bone metabolism therapeutics market, including top companies benchmarking. The key companies studied in this report are Amgen Inc., Abbott Laboratories, Genzyme Corporation, Merck & Co. Inc. and Novartis AG.
  • Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorders therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents
Product Code: GBIHC123MR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Bone Metabolism Therapeutics Market to 2018-Market Overview

  • 3.1. Introduction
    • 3.1.1. Revenue
    • 3.1.2. Annual Cost of Treatment
    • 3.1.3. Treatment Usage Patterns

4. Bone Metabolism Therapeutics Market to 2018-Geographical Landscape

  • 4.1. Revenue Analysis by Geography
  • 4.2. The US
    • 4.2.1. Revenue
    • 4.2.2. Annual Cost of Treatment
    • 4.2.3. Treatment Usage Patterns
  • 4.3. Top Five Countries of Europe
    • 4.3.1. Revenue
    • 4.3.2. Annual Cost of Treatment
    • 4.3.3. Treatment Usage Patterns
  • 4.4. Japan
    • 4.4.1. Revenue
    • 4.4.2. Annual Cost of Treatment
    • 4.4.3. Treatment Usage Patterns

5. Bone Metabolism Therapeutics Market to 2018-Therapeutic Landscape

  • 5.1. Osteoporosis Therapeutics Market
    • 5.1.1. Introduction
    • 5.1.2. Revenue
    • 5.1.3. Annual Cost of Treatment
    • 5.1.4. Treatment Usage Patterns
    • 5.1.5. Treatment Flow Algorithm
    • 5.1.6. Drivers and Barriers for the Osteoporosis Therapeutics Market
  • 5.2. Paget's Disease of Bone Therapeutics Market
    • 5.2.1. Introduction
    • 5.2.2. Revenue
    • 5.2.3. Annual Cost of Treatment
    • 5.2.4. Treatment Usage Patterns
    • 5.2.5. Treatment Flow Algorithm
    • 5.2.6. Drivers and Barriers for the Paget's Disease of Bone Therapeutics Market
  • 5.3. Hyperparathyroidism Therapeutics Market
    • 5.3.1. Introduction
    • 5.3.2. Revenue
    • 5.3.3. Annual Cost of Treatment
    • 5.3.4. Treatment Usage Patterns
    • 5.3.5. Treatment Flow Algorithm
    • 5.3.6. Drivers and Barriers for the Hyperparathyroidism Therapeutics Market
  • 5.4. Bone Metastases Therapeutics Market
    • 5.4.1. Introduction
    • 5.4.2. Revenue
    • 5.4.3. Annual Cost of Treatment
    • 5.4.4. Treatment Usage Patterns
    • 5.4.5. Treatment Flow Algorithm
    • 5.4.6. Drivers and Barriers for the Bone Metastases Therapeutics Market

6. Bone Metabolism Therapeutics Market to 2018-Pipeline Analysis

  • 6.1. Introduction
  • 6.2. Bone Metabolism Therapeutics Market-Pipeline Assessment by Clinical Phase of Development
    • 6.2.1. Filed Molecules
    • 6.2.2. Phase III
    • 6.2.3. Phase II
    • 6.2.4. Phase I
    • 6.2.5. Preclinical Phase
    • 6.2.6. Discovery Phase
  • 6.3. Profiles of Promising Molecules in the Bone Metabolism Therapeutics Market
    • 6.3.1. Alpharadin (radium-223 chloride)
    • 6.3.2. Orazol (Zoledronic acid)
    • 6.3.3. Xgeva (denosumab)
    • 6.3.4. Boniva (ibandronate sodium hydrate)
    • 6.3.5. Odanacatib (odanacatib)
    • 6.3.6. GTH-42V
    • 6.3.7. Viviant (bazedoxifene)

7. Bone Metabolism Therapeutics Market to 2018-Competitive Profiling

  • 7.1. Competitive Profiling
    • 7.1.1. Amgen Inc.
    • 7.1.2. Abbott Laboratories
    • 7.1.3. Genzyme Corporation
    • 7.1.4. Merck & Co., Inc.
    • 7.1.5. Novartis AG

8. Bone Metabolism Therapeutics Market to 2018-Strategic Consolidations

  • 8.1. Mergers and Acquisitions
    • 8.1.1. Segmentation by Deal Value
    • 8.1.2. Segmentation by Geography
  • 8.2. Co-development Deals
    • 8.2.1. Summary of Co-development Deals
  • 8.3. Licensing Deals
    • 8.3.1. Summary of Licensing Deals

9. Bone Metabolism Therapeutics Market to 2018-Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Sources
  • 9.4. Research Methodology
    • 9.4.1. Coverage
    • 9.4.2. Secondary Research
    • 9.4.3. Primary Research
  • 9.5. Therapeutic Landscape
    • 9.5.1. Epidemiology-based Forecasting
    • 9.5.2. Market Size by Geography
  • 9.6. Geographical Landscape
  • 9.7. Pipeline Analysis
  • 9.8. Competitive Landscape
    • 9.8.1. Expert Panel Validation
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Bone Metabolism Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 2: Bone Metabolism Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018
  • Table 3: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 4: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
  • Table 5: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 6: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
  • Table 7: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 8: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018
  • Table 9: Bone Metabolism Therapeutics Market, The US, Revenue ($bn), 2002-2010
  • Table 10: Bone Metabolism Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018
  • Table 11: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010
  • Table 12: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2018
  • Table 13: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2010
  • Table 14: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018
  • Table 15: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010
  • Table 16: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2018
  • Table 17: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue ($bn), 2002-2010
  • Table 18: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue Forecasts ($bn), 2010-2018
  • Table 19: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010
  • Table 20: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2018
  • Table 21: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2010
  • Table 22: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2018
  • Table 23: Bone Metabolism Therapeutics Market, Japan, Revenue ($bn), 2002-2010
  • Table 24: Bone Metabolism Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2018
  • Table 25: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010
  • Table 26: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018
  • Table 27: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2010
  • Table 28: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018
  • Table 29: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 30: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018
  • Table 31: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 32: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018
  • Table 33: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 34: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
  • Table 35: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 36: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
  • Table 37: Paget's Disease of Bone Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 38: Paget's Disease of Bone Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018
  • Table 39: Paget's Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
  • Table 40: Paget's Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018
  • Table 41: Paget's Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 42: Paget's Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
  • Table 43: Paget's Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 44: Paget's Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
  • Table 45: Hyperparathyroidism Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 46: Hyperparathyroidism Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018
  • Table 47: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
  • Table 48: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018
  • Table 49: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 50: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
  • Table 51: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 52: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018
  • Table 53: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 54: Bone Metastases Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018
  • Table 55: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
  • Table 56: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018
  • Table 57: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 58: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018
  • Table 59: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010
  • Table 60: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2018
  • Table 61: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, NDA-filed Molecules,2011
  • Table 62: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase III Molecules,2011
  • Table 63: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase II Molecules,2011
  • Table 64: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase I Molecules,2011
  • Table 65: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase Molecules,2011
  • Table 66: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Discovery Phase Molecules,2011
  • Table 67: Bone Metabolism Therapeutics Market, Global, M&A, 2009-2011
  • Table 68: Bone Metabolism Therapeutics Market, M&A Deals, by Value ($m) 2009-2011
  • Table 69: Bone Metabolism Therapeutics Market, Co-development, by Geography, 2009-2011
  • Table 70: Bone Metabolism Therapeutics Market, Licensing Deals, by Geography, 2009-2011

List of Figures

  • Figure 1: Bone Metabolism Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2018
  • Figure 2: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018
  • Figure 3: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018
  • Figure 4: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2018
  • Figure 5: Bone Metabolism Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2018
  • Figure 6: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2018
  • Figure 7: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2018
  • Figure 8: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2018
  • Figure 9: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue Forecasts ($bn), 2002-2018
  • Figure 10: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2018
  • Figure 11: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2018
  • Figure 12: Bone Metabolism Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2018
  • Figure 13: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2018
  • Figure 14: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2018
  • Figure 15: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2018
  • Figure 16: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2018
  • Figure 17: Osteoporosis Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018
  • Figure 18: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018
  • Figure 19: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018
  • Figure 20: Osteoporosis Therapeutics Market, Treatment Flow Algorithm
  • Figure 21: Osteoporosis, Market Drivers and Barriers
  • Figure 22: Paget's Disease of Bone Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018
  • Figure 23: Paget's Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018
  • Figure 24: Paget's Disease of Bone Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018
  • Figure 25: Paget's Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018
  • Figure 26: Paget's Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018
  • Figure 27: Paget's Disease of Bone Therapeutics Market, Treatment Flow Algorithm
  • Figure 28: Paget's Disease of Bone, Market Drivers and Barriers
  • Figure 29: Hyperparathyroidism Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018
  • Figure 30: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018
  • Figure 31: Hyperparathyroidism Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018
  • Figure 32: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018
  • Figure 33: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018
  • Figure 34: Hyperparathyroidism Therapeutics Market, Treatment Flow Algorithm
  • Figure 35: Hyperparathyroidism, Market Drivers and Barriers
  • Figure 36: Bone Metastases Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018
  • Figure 37: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018
  • Figure 38: Bone Metastases Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018
  • Figure 39: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018
  • Figure 40: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2018
  • Figure 41: Bone Metastases Therapeutics Market, Treatment Flow Algorithm
  • Figure 42: Bone Metastases, Market Drivers and Barriers
  • Figure 43: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
  • Figure 44: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
  • Figure 45: Bone Metabolism Therapeutics Market, Global, SWOT - Amgen Inc.
  • Figure 46: Bone Metabolism Therapeutics Market, Global, SWOT - Abbott Laboratories
  • Figure 47: Bone Metabolism Therapeutics Market, Global, SWOT - Genzyme Corporation
  • Figure 48: Bone Metabolism Therapeutics Market, Global, SWOT - Merck & Co., Inc.
  • Figure 49: Bone Metabolism Therapeutics Market, Global, SWOT - Novartis AG
  • Figure 50: Bone Metabolism Therapeutics Market, Global, Deals by Indication, 2009-2011
  • Figure 51: Bone Metabolism Therapeutics Market, M&A Deals, by Value ($m) 2009-2011
  • Figure 52: Bone Metabolism Therapeutics Market, M&A Deals, by Geography ($m) 2009-2011
  • Figure 53: Bone Metabolism Therapeutics Market, Licensing Deals, by Geography, 2009-2011
  • Figure 54: GBI Research Market Forecasting Model
Back to Top